抗VEGF药物在新生血管性青光眼治疗中的应用

新生血管性青光眼（neovascular glaucoma,NVG）是继发于眼底缺血性疾病的一类难治性青光眼.既往抗青光眼药物和手术治疗失败率较高.近几年抗血管内皮细胞生长因子（anti-vascu-lar endothelial growth factor,anti-VEGF）药物逐渐用于辅助小梁切除术、引流装置植入术、睫状体光凝/冷冻术、玻璃体切除术等综合治疗.其抗血管形成和抗成纤维细胞的特性可以有效改善视网膜缺血、迅速消除眼前段新生血管、防止术中术后前房出血和延长滤过泡寿命,明显提高了NVG手术的成功率,尤其是早期治疗的成功率.但抗VEGF在NVG治疗中的时机选择及安全性等方面还需进一步研究.

Anti-VEGF for the treatment of neovascular glaucoma

Neovascular glaucoma （NVG） is regarded as refractory glaucoma secondary to retinal ischemia.Previous anti-glaucoma drugs and surgeries present low therapeutic effect.Recently anti-vascular endothelial growth factor （anti-VEGF） agent has been used as an adjunction for NVG comprehensive treatment,including trabeculectomy,drainage valve implantation,cyclophotocoagulation/cyclocryotherapy and vitrectomy etc.The antiangiogenic and antifibroblastic properties of anti-VEGF agents have shown great promise in reducing retinal ischemia,rapid regression of anterior segment neovascularization,preventing intra-and post-operative hyphema and improving the filtering bled,which effectively increase the operative successful rate,especially for NVG in the early stage.However,injection timing,safty and other aspects of anti-VEGF therapy in NVG treatment still need further study.